"As early participants in these innovative drug reimbursement processes, AstraZeneca and Daiichi Sankyo are pleased to accelerate access to innovative treatments for Canadian patients ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Shares in Esperion Therapeutics lost more than half of their value after it disclosed a dispute with Daiichi Sankyo on a $300 million milestone payment relating to cholesterol drug Nexletol.

Dublin, May 23, 2025 (GLOBE NEWSWIRE) -- The "Atherosclerosis Market - A Global and Regional Analysis: Focus on Drug Class and Region - Analysis and Forecast, 2025-2035" report has been added to ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Additionally, only two of the top 25 companies in the industry—Daiichi Sankyo (6%) and Novartis (0.6%)—had sequential revenue increases in the first quarter, though analysts warn that fourth ...

“Every advance in cancer care begins with a single idea — and a deep commitment to patients,” says Dr. Michael Zaiac, Head of European Medical Affairs Oncology, Daiichi Sankyo. “At Daiichi ...

The addition of lurbinectedin — a novel alkylating agent and transcription inhibitor — to first-line maintenance immunotherapy for extensive-stage small cell lung cancer (ES-SCLC) improved ...